At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Determine Efficacy and Safety of BXCL501 In Agitation Associated With Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Sublingual film containing dexmedetomidine (BXCL501) and Placebo Film for Agitation and 4 related conditions. Completed, enrolled 380 participants across 15 sites.
Detailed Summary
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia. The BXCL501-301 study is designed to characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of DEX, HCl) in agitation associated with schizophrenia, schizoaffective disorder or schizophreniform disorder.
Study Details
Timeline
Arms & Interventions
Sublingual film containing 120 Micrograms dexmedetomidine
Sublingual film containing 180 Micrograms dexmedetomidine
Sublingual placebo film
Interventions
Sublingual film containing dexmedetomidine (BXCL501)
Placebo Film for BXCL501